HR 5925 RFS 
‘‘(II) state the specific roles and 
responsibilities of the relevant Na-
tional Drug Control Program Agen-
cies for implementing that strategy; 
and 
‘‘(III) identify the specific re-
sources required to enable the relevant 
National 
Drug 
Control 
Program 
Agencies to implement that strategy. 
‘‘(ii) SPECIFIC CONTENT RELATED TO 
DRUG
TUNNELS
BETWEEN
THE
UNITED 
STATES
AND
MEXICO.—The Southwest 
Border Counternarcotics Strategy shall in-
clude— 
‘‘(I) a strategy to end the con-
struction and use of tunnels and sub-
terranean passages that cross the 
international 
border 
between 
the 
United States and Mexico for the pur-
pose of illegal trafficking of drugs 
across such border; and 
‘‘(II) recommendations for crimi-
nal penalties for persons who con-
struct or use such a tunnel or sub-
terranean passage for such a purpose. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00037
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(C) REQUIREMENT FOR NORTHERN BOR-
DER COUNTERNARCOTICS STRATEGY.— 
‘‘(i) PURPOSES.—The Northern Bor-
der Counternarcotics Strategy shall— 
‘‘(I) set forth the strategy of the 
Federal Government for preventing 
the illegal trafficking of drugs across 
the international border between the 
United States and Canada, including 
through ports of entry and between 
ports of entry on the border; 
‘‘(II) state the specific roles and 
responsibilities of each relevant Na-
tional Drug Control Program Agency 
for implementing the strategy; 
‘‘(III) identify the specific re-
sources required to enable the relevant 
National 
Drug 
Control 
Program 
Agencies to implement the strategy; 
‘‘(IV) be designed to promote, 
and not hinder, legitimate trade and 
travel; and 
‘‘(V) reflect the unique nature of 
small communities along the inter-
national border between the United 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00038
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
States and Canada, ongoing coopera-
tion and coordination with Canadian 
law, 
enforcement 
authorities, 
and 
variations in the volumes of vehicles 
and 
pedestrians 
crossing 
through 
ports of entry along the international 
border between the United States and 
Canada. 
‘‘(ii) SPECIFIC CONTENT RELATED TO 
CROSS-BORDER
INDIAN
RESERVATIONS.— 
The Northern Border Counternarcotics 
Strategy shall include— 
‘‘(I) a strategy to end the illegal 
trafficking of drugs to or through In-
dian reservations on or near the inter-
national border between the United 
States and Canada; and 
‘‘(II) recommendations for addi-
tional assistance, if any, needed by 
Tribal law enforcement agencies relat-
ing to the strategy, including an eval-
uation of Federal technical and finan-
cial assistance, infrastructure capacity 
building, and interoperability defi-
ciencies. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00039
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(3) CLASSIFIED INFORMATION.—Any contents 
of the National Drug Control Strategy that involve 
information properly classified under criteria estab-
lished by an Executive order shall be presented to 
Congress separately from the rest of the National 
Drug Control Strategy. 
‘‘(4) SELECTION
OF
DATA
AND
INFORMA-
TION.—In selecting data and information for inclu-
sion in the Strategy, the Director shall ensure— 
‘‘(A) the inclusion of data and information 
that will permit analysis of current trends 
against previously compiled data and informa-
tion where the Director believes such analysis 
enhances long-term assessment of the National 
Drug Control Strategy; and 
‘‘(B) the inclusion of data and information 
to permit a standardized and uniform assess-
ment of the effectiveness of drug treatment pro-
grams in the United States. 
‘‘(d) ANNUAL PERFORMANCE SUPPLEMENT.—Not 
later than the first Monday in February of each year fol-
lowing the year in which the National Drug Control Strat-
egy is submitted pursuant to subsection (a)(2), the Direc-
tor shall submit to the appropriate congressional commit-
tees a supplement to the Strategy that shall include— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00040
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(1) annual and, to the extent practicable, 
quarterly quantifiable and measurable objectives and 
specific targets to accomplish long-term quantifiable 
goals specified in the Strategy; and 
‘‘(2) for each year covered by the Strategy, a 
performance evaluation plan for each goal listed in 
the Strategy for each National Drug Control Pro-
gram Agency, including— 
‘‘(A) specific performance measures for 
each National Drug Control Program Agency 
and each such agency’s related programs and 
activities; 
‘‘(B) annual and, to the extent practicable, 
quarterly objectives and targets for each per-
formance measure; and 
‘‘(C) an estimate of Federal funding and 
other resources needed to achieve each perform-
ance objective and target. 
‘‘(e) SUBMISSION OF REVISED STRATEGY.— 
‘‘(1) IN GENERAL.—The President may submit 
to Congress a revised National Drug Control Strat-
egy that meets the requirements of this section— 
‘‘(A) at any time, upon a determination of 
the President, in consultation with the Director, 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00041
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
that the National Drug Control Strategy in ef-
fect is not sufficiently effective; or 
‘‘(B) if a new President or Director takes 
office. 
‘‘(2) NO SUBMISSION.—In each year the Presi-
dent does not submit a National Drug Control 
Strategy or a revised National Drug Control Strat-
egy, the Director shall evaluate the efficacy and ap-
propriateness of the goals of the National Drug Con-
trol Strategy and include a statement affirming the 
adequacy of the goals in the performance supple-
ment under subsection (d). 
‘‘(f) FAILURE OF PRESIDENT TO SUBMIT NATIONAL 
DRUG CONTROL STRATEGY.—If the President does not 
submit a National Drug Control Strategy to Congress in 
accordance with subsection (a)(2), not later than 5 days 
after the first Monday in February following the year in 
which the term of the President commences, the President 
shall send a notification to the appropriate congressional 
committees— 
‘‘(1) explaining why the Strategy was not sub-
mitted; and 
‘‘(2) specifying the date by which the Strategy 
will be submitted. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00042
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘§ 1006. Development of an annual national drug con-
trol assessment 
‘‘(a) TIMING.—Not later than the first Monday in 
February of each year, the Director shall submit to the 
President, Congress, and the appropriate congressional 
committees, a report assessing the progress of each Na-
tional Drug Control Program Agency toward achieving 
each goal, objective, and target contained in the National 
Drug Control Strategy applicable to the prior fiscal year. 
‘‘(b) PROCESS FOR DEVELOPMENT OF THE ANNUAL 
ASSESSMENT.—Not later than November 1 of each year, 
the head of each National Drug Control Program Agency 
shall submit, in accordance with guidance issued by the 
Director, to the Director an evaluation of progress by the 
agency with respect to the National Drug Control Strategy 
goals using the performance measures for the agency de-
veloped under this chapter, including progress with respect 
to— 
‘‘(1) success in achieving the goals of the Na-
tional Drug Control Strategy; 
‘‘(2) success in reducing domestic and foreign 
sources of illegal drugs; 
‘‘(3) success in expanding access to and in-
creasing the effectiveness of substance use disorder 
treatment; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00043
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(4) success in protecting the borders of the 
United States (and in particular the Southwestern 
border of the United States) from penetration by il-
legal narcotics; 
‘‘(5) success in reducing crime associated with 
drug use in the United States; 
‘‘(6) success in reducing the negative health 
and social consequences of drug use in the United 
States; and 
‘‘(7) implementation of substance use disorder 
treatment and prevention programs in the United 
States and improvements in the adequacy and effec-
tiveness of such programs. 
‘‘(c) CONTENTS OF THE ANNUAL ASSESSMENT.— 
The Director shall include in the annual assessment re-
quired under subsection (a)— 
‘‘(1) a summary of each evaluation received by 
the Director under subsection (b); 
‘‘(2) a summary of the progress of each Na-
tional Drug Control Program Agency toward the 
National Drug Control Strategy goals of the agency 
using the performance measures for the agency de-
veloped under this chapter; 
‘‘(3) an assessment of the effectiveness of each 
National Drug Control Program Agency and pro-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00044
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
gram in achieving the National Drug Control Strat-
egy for the previous year, including a specific evalua-
tion of whether the applicable goals, measures, ob-
jectives, and targets for the previous year were met; 
‘‘(4) for each National Drug Control Program 
Agency that administers grant programs, an evalua-
tion of the effectiveness of each grant program, in-
cluding an accounting of the funds disbursed by the 
program in the prior year and a summary of how 
those funds were used by the grantees and sub- 
grantees during that period; 
‘‘(5) a detailed accounting of the amount of 
funds obligated by each National Drug Control Pro-
gram Agency in carrying out the responsibilities of 
that agency under the Strategy; 
‘‘(6) an assessment of the effectiveness of any 
Emerging Threat Response Plan in effect for the 
previous year, including a specific evaluation of 
whether the objectives and targets were met and rea-
sons for the success or failure of the previous year’s 
plan; 
‘‘(7) a detailed accounting of the amount of 
funds obligated during the previous fiscal year for 
carrying out the campaign under section 1009(d), 
including each recipient of funds, the purpose of 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00045
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
each expenditure, the amount of each expenditure, 
any available outcome information, and any other in-
formation necessary to provide a complete account-
ing of the funds expended; and 
‘‘(8) the assessments required under this sub-
section shall be based on the Performance Measure-
ment System describe in subsection (d). 
‘‘(d) PERFORMANCE MEASUREMENT SYSTEM.—The 
Director shall include in the annual assessment required 
under subsection (a) a national drug control performance 
measurement system, that— 
‘‘(1) develops annual, 2-year, and 5-year per-
formance measures, objectives, and targets for each 
National Drug Control Strategy goal and objective 
established for reducing drug use, availability, and 
the consequences of drug use; 
‘‘(2) describes the sources of information and 
data that will be used for each performance measure 
incorporated into the performance measurement sys-
tem; 
‘‘(3) identifies major programs and activities of 
the National Drug Control Program Agencies that 
support the goals and annual objectives of the Na-
tional Drug Control Strategy; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00046
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(4) evaluates the contribution of demand re-
duction and supply reduction activities implemented 
by each National Drug Control Program Agency in 
support of the National Drug Control Strategy; 
‘‘(5) monitors consistency between the drug-re-
lated goals, measures, targets, and objectives of the 
National Drug Control Program Agencies and en-
sures that each agency’s goals and budgets support, 
and are fully consistent with, the National Drug 
Control Strategy; and 
‘‘(6) coordinates the development and imple-
mentation of national drug control data collection 
and reporting systems to support policy formulation 
and performance measurement, including an assess-
ment of— 
‘‘(A) the quality of current drug use meas-
urement instruments and techniques to measure 
supply reduction and demand reduction activi-
ties; 
‘‘(B) the adequacy of the coverage of exist-
ing national drug use measurement instruments 
and techniques to measure the illicit drug user 
population and groups that are at risk for illicit 
drug use; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00047
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(C) the adequacy of the coverage of exist-
ing national treatment outcome monitoring sys-
tems to measure the effectiveness of substance 
use disorder treatment in reducing illicit drug 
use and criminal behavior during and after the 
completion of substance use disorder treatment; 
and 
‘‘(D) the actions the Director shall take to 
correct any deficiencies and limitations identi-
fied pursuant to subparagraphs (A), (B), and 
(C). 
‘‘(e) MODIFICATIONS.—A description of any modi-
fications made during the preceding year to the national 
drug performance measurement system described in sub-
section (d) shall be included in each report submitted 
under subsection (a). 
‘‘(f) ANNUAL REPORT ON CONSULTATION.—The Di-
rector shall include in the annual assessment required 
under subsection (a)— 
‘‘(1) a detailed description of how the Office 
has consulted with and assisted State, local, and 
Tribal governments with respect to the formulation 
and implementation of the National Drug Control 
Strategy and other relevant issues; and 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00048
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(2) a general review of the status of, and 
trends in, demand reduction activities by private sec-
tor entities and community-based organizations, in-
cluding faith-based organizations, to determine their 
effectiveness and the extent of cooperation, coordina-
tion, and mutual support between such entities and 
organizations and Federal, State, local, and Tribal 
government agencies. 
‘‘(g) PERFORMANCE-BUDGET COORDINATOR.— 
‘‘(1) DESIGNATION.—The Director shall des-
ignate or appoint a United States Performance- 
Budget Coordinator to— 
‘‘(A) ensure the Director has sufficient in-
formation necessary to analyze the performance 
of each National Drug Control Program Agen-
cy, the impact Federal funding has had on the 
goals in the Strategy, and the likely contribu-
tions to the goals of the Strategy based on 
funding levels of each National Drug Control 
Program Agency, to make an independent as-
sessment of the budget request of each agency 
under section 1004; 
‘‘(B) advise the Director on agency budg-
ets, performance measures and targets, and ad-
ditional data and research needed to make in-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00049
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
formed policy decisions under sections 1004 and 
1005; and 
‘‘(C) other duties as may be determined by 
the Director with respect to measuring or as-
sessing performance or agency budgets. 
‘‘(2) DETERMINATION OF POSITION.—The Di-
rector shall determine whether the coordinator posi-
tion is a noncareer appointee in the Senior Executive 
Service or a career appointee at the GS–15 level (or 
equivalent) or above. 
‘‘§ 1007. Monitoring and evaluation of national drug 
control program 
‘‘(a) IN GENERAL.—The Director shall monitor im-
plementation of the National Drug Control Program and 
the activities of the National Drug Control Program Agen-
cies in carrying out the goals and objectives of the Na-
tional Drug Control Strategy including— 
‘‘(1) conducting program and performance au-
dits and evaluations; and 
‘‘(2) requesting assistance from the Inspector 
General of the relevant agency in such audits and 
evaluations. 
‘‘(b) ACCOUNTING OF FUNDS EXPENDED.—(1) Not 
later than February 1 of each year, in accordance with 
guidance issued by the Director, the head of each National 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00050
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
Drug Control Program Agency shall submit to the Direc-
tor a detailed accounting of all funds expended by the 
agency for National Drug Control Program activities dur-
ing the previous fiscal year and shall ensure such detailed 
accounting is authenticated for the previous fiscal year by 
the Inspector General for such agency prior to the submis-
sion to the Director as frequently as determined by the 
Inspector General but not less frequently that every 3 
years. 
‘‘(2) The Director shall submit to Congress not later 
than April 1 of each year the information submitted to 
the Director under paragraph (1). 
‘‘(c) NOTIFICATION.—The Director shall notify any 
National Drug Control Program Agency if its activities 
are not in compliance with the responsibilities of the agen-
cy under the National Drug Control Strategy, transmit 
a copy of each such notification to the President and the 
appropriate congressional committees, and maintain a 
copy of each such notification. 
‘‘(d) RECOMMENDATIONS.—The Director shall make 
such recommendations to the President and the appro-
priate congressional committees as the Director deter-
mines are appropriate regarding changes in the organiza-
tion, management, and budgets of the National Drug Con-
trol Program Agencies, and changes in the allocation of 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00051
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
personnel to and within those agencies, to implement the 
policies, goals, objectives, and priorities established under 
section 1002(c)(1) and the National Drug Control Strat-
egy. 
‘‘(e) AUTHORIZATION, DEVELOPMENT, AND IMPLE-
MENTATION OF A COORDINATED TRACKING SYSTEM.— 
‘‘(1) ESTABLISHMENT.—The Director shall es-
tablish a coordinated tracking system of federally- 
funded initiatives and grant programs which shall— 
‘‘(A) be the central repository of all drug 
control grants; 
‘‘(B) identify duplication, overlap, or gaps 
in funding to provide increased accountability of 
federally-funded grants for substance use dis-
order treatment, prevention, and enforcement; 
‘‘(C) identify impediments that applicants 
currently have in the grant application process 
with applicable agencies; and 
‘‘(D) be developed and maintained by the 
Office with the support of designated National 
Drug Control Program Agencies and any other 
agency determined by the Director. 
‘‘(2) PERFORMANCE
METRICS.—The Director 
shall identify metrics and achievable goals for grant 
recipients in furtherance of the Strategy. Such 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00052
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
metrics shall be used to measure how effective each 
federally funded initiative is in achieving the objec-
tives of the Strategy and to enable comparisons of 
federally funded initiatives to identify those that are 
the most cost effective. 
‘‘(3) 
GRANT
APPLICATION
STANDARDIZA-
TION.—To reduce the administrative burden on 
grant applicants and improve oversight of Federal 
funds, the Director, in consultation with the head of 
each National Drug Control Program Agency, shall 
develop a plan for coordinating and standardizing 
drug control grant application processes and develop 
a joint application to be used by all National Drug 
Control Program Agencies. 
‘‘(4) CENTRAL
PORTAL.—The Director shall 
maintain on the public, electronic portal of the Of-
fice a list all drug control grant programs available 
in a central location. The head of each National 
Drug Control Program Agency shall provide a com-
plete list of all drug control program grant programs 
to the Director and annually update such list. 
‘‘(5) REPORT
TO
CONGRESS.—The Director 
shall include in the assessment submitted to Con-
gress under section 1006 an assessment on progress 
under this section. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00053
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘§ 1008. Coordination and oversight of the national 
drug control program 
‘‘(a) IN GENERAL.—The Director shall coordinate 
and oversee the implementation by the National Drug 
Control Program Agencies of the policies, goals, objectives, 
and priorities established under section 1002(c)(1) and 
the fulfillment of the responsibilities of such agencies 
under the National Drug Control Strategy and make rec-
ommendations to National Drug Control Program Agency 
heads with respect to implementation of National Drug 
Control Programs. 
‘‘(b) DETAILING EMPLOYEES
TO OTHER AGEN-
CIES.— 
‘‘(1) REQUEST.—The Director may request the 
head of an agency or program of the Federal Gov-
ernment to place agency personnel who are engaged 
in drug control activities on temporary detail to an-
other agency in order to implement the National 
Drug Control Strategy. 
‘‘(2) AGENCY COMPLIANCE.—The head of the 
agency shall comply with any request made under 
paragraph (1). 
‘‘(3) MAXIMUM NUMBER OF DETAILEES.—The 
maximum number of personnel who may be detailed 
to another agency (including the Office) under this 
subsection during any fiscal year is— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00054
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(A) for the Department of Defense, 50; 
and 
‘‘(B) for any other agency, 10. 
‘‘(c) DIRECTING FEDERAL FUNDING.—The Director 
may transfer funds made available to a National Drug 
Control Program Agency for National Drug Control Strat-
egy programs and activities to another account within 
such agency or to another National Drug Control Program 
Agency for National Drug Control Strategy programs and 
activities, except that— 
‘‘(1) the authority under this subsection may be 
limited in an annual appropriations Act or other 
provision of Federal law; 
‘‘(2) the Director may exercise the authority 
under this subsection only with the concurrence of 
the head of each affected agency; 
‘‘(3) in the case of an interagency transfer, the 
total amount of transfers under this subsection may 
not exceed 3 percent of the total amount of funds 
made available for National Drug Control Strategy 
programs and activities to the agency from which 
those funds are to be transferred; 
‘‘(4) funds transferred to an agency under this 
subsection may only be used to increase the funding 
for programs or activities authorized by law; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00055
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(5) the Director shall— 
‘‘(A) submit to the appropriate congres-
sional committees and any other applicable 
committee of jurisdiction, a reprogramming or 
transfer request in advance of any transfer 
under this subsection in accordance with the 
regulations of each affected agency; and 
‘‘(B) annually submit to the appropriate 
congressional committees a report describing 
the effect of all transfers of funds made pursu-
ant to this subsection or section 1004(f) during 
the 12-month period preceding the date on 
which the report is submitted; and 
‘‘(6) funds may only be used for— 
‘‘(A) expansion of demand reduction activi-
ties; 
‘‘(B) interdiction of illicit drugs on the 
high seas, in United States territorial waters, 
and at United States ports of entry by officers 
and employees of National Drug Control Pro-
gram Agencies and domestic and foreign law 
enforcement officers; 
‘‘(C) accurate assessment and monitoring 
of international drug production and interdic-
tion programs and policies; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00056
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(D) activities to facilitate and enhance 
the sharing of domestic and foreign intelligence 
information among National Drug Control Pro-
gram Agencies related to the production and 
trafficking of drugs in the United States and 
foreign countries; 
‘‘(E) activities to prevent the diversion of 
prescription drugs for illicit use; and 
‘‘(F) research related to any of these ac-
tivities. 
‘‘(d) DIRECTING FEDERAL FUNDING TO RESPOND 
TO EMERGING THREATS.— 
‘‘(1) IN GENERAL.—The Director may transfer 
funds made available to a National Drug Control 
Program Agency for National Drug Control Strategy 
programs and activities to another account within 
such agency or to another National Drug Control 
Program Agency for National Drug Control Strategy 
programs and activities to implement the provisions 
of a plan developed under section 1009, except 
that— 
‘‘(A) the authority under this subsection 
may be limited in an annual appropriations Act 
or other provision of Federal law; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00057
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(B) the Director may exercise the author-
ity under this subsection only with the concur-
rence of the head of each affected agency; 
‘‘(C) in the case of an interagency transfer, 
the total amount of transfers under this sub-
section may not exceed 10 percent of the total 
amount of funds made available for National 
Drug Control Strategy programs and activities 
to the agency from which those funds are to be 
transferred; 
‘‘(D) funds transferred to an agency under 
this subsection may only be used to increase the 
funding for programs or activities authorized by 
law; 
‘‘(E) no transfer of funds under this sub-
section may result in a reduction in total Fed-
eral expenditures for substance use disorder 
treatment; 
‘‘(F) the Director shall— 
‘‘(i) submit to the appropriate con-
gressional committees and any other appli-
cable committee of jurisdiction, a re-
programming or transfer request in ad-
vance of any transfer under this subsection 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00058
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
in accordance with the regulations of each 
affected agency; and 
‘‘(ii) annually submit to the appro-
priate congressional committees a report 
describing the effect of all transfers of 
funds made pursuant to this subsection or 
section 1004(f) during the 12-month pe-
riod preceding the date on which the report 
is submitted; and 
‘‘(G) funds may only be used for— 
‘‘(i) expansion of demand reduction 
activities; 
‘‘(ii) interdiction of illicit drugs on the 
high seas, in United States territorial 
waters, and at United States ports of entry 
by officers and employees of National 
Drug Control Program Agencies and do-
mestic and foreign law enforcement offi-
cers; 
‘‘(iii) accurate assessment and moni-
toring of international drug production and 
interdiction programs and policies; 
‘‘(iv) activities to facilitate and en-
hance the sharing of domestic and foreign 
intelligence information among National 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00059
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
Drug Control Program Agencies related to 
the production and trafficking of drugs in 
the United States and foreign countries; 
‘‘(v) activities to prevent the diversion 
of prescription drugs for illicit use; and 
‘‘(vi) research related to any of these 
activities. 
‘‘(2) INADEQUACY OF TRANSFER.—In the event 
the authority under this subsection is inadequate to 
implement the provisions of a plan developed under 
section 1009, the Director shall submit a request for 
funding to the appropriate congressional committees 
within 30 days after the date on which the Director 
determines there is a need for additional funding. 
‘‘(e) FUND CONTROL NOTICES.— 
‘‘(1) IN GENERAL.—The Director may issue to 
the head of a National Drug Control Program Agen-
cy a fund control notice to ensure compliance with 
the National Drug Control Program Strategy. A 
fund control notice may direct that all or part of an 
amount appropriated to the National Drug Control 
Program Agency account be obligated by— 
‘‘(A) months, fiscal year quarters, or other 
time periods; and 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00060
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(B) activities, functions, projects, or ob-
ject classes. 
‘‘(2) UNAUTHORIZED OBLIGATION OR EXPENDI-
TURE
PROHIBITED.—An officer or employee of a 
National Drug Control Program Agency shall not 
make or authorize an expenditure or obligation con-
trary to a fund control notice issued by the Director. 
‘‘(3) DISCIPLINARY ACTION FOR VIOLATION.— 
In the case of a violation of paragraph (2) by an of-
ficer or employee of a National Drug Control Pro-
gram Agency, the head of the agency, upon the re-
quest of and in consultation with the Director, may 
subject the officer or employee to appropriate ad-
ministrative 
discipline, 
including, 
when 
cir-
cumstances warrant, suspension from duty without 
pay or removal from office. 
‘‘(4) CONGRESSIONAL NOTICE.—Not later than 
5 days after issuance of a fund control notice, the 
Director shall submit a copy of such fund control 
notice to the appropriate congressional committees 
and make such notice publicly available. 
‘‘(5) RESTRICTIONS.—The Director may not 
issue a fund control notice to direct that all or part 
of an amount appropriated to the National Drug 
Control Program Agency account be obligated, modi-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00061
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
fied, or altered in any manner contrary, in whole or 
in part, to a specific appropriation or statute. 
‘‘(f) EXCLUSIONS.—The authorities described under 
subsections (c), (d), and (e) do not apply to any program 
under subchapter II or III. 
‘‘(g) FOREIGN ASSISTANCE ACT PARTICIPATION.— 
The Director may participate in the drug certification 
process pursuant to section 490 of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2291j) and section 706 of the 
Department of State Authorization Act for Fiscal Year 
2003 (22 U.S.C. 229j–l). 
‘‘(h) CERTIFICATIONS OF POLICY CHANGES TO DI-
RECTOR.— 
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
the head of a National Drug Control Program Agen-
cy shall, unless exigent circumstances require other-
wise, notify the Director in writing regarding any 
proposed change in policies relating to the activities 
of that agency under the National Drug Control 
Program prior to implementation of such change. 
The Director shall promptly review such proposed 
change and certify to the head of that agency in 
writing whether such change is consistent with the 
National Drug Control Strategy. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00062
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(2) EXCEPTION.—If prior notice of a proposed 
change under paragraph (1) is not practicable— 
‘‘(A) the head of the National Drug Con-
trol Program Agency shall notify the Director 
of the proposed change as soon as practicable; 
and 
‘‘(B) upon such notification, the Director 
shall review the change and certify to the head 
of that agency in writing whether the change is 
consistent with the National Drug Control 
Strategy. 
‘‘(i) WORK IN CONJUNCTION WITH ASSISTANT FOR 
NATIONAL SECURITY AFFAIRS.—The Director shall, in 
any matter affecting national security interests, work in 
conjunction with the Assistant to the President for Na-
tional Security Affairs. 
‘‘(j) AUTHORITIES NOT DEROGATED.—Nothing in 
this chapter shall be construed as derogating the authori-
ties and responsibilities of the head of any agency, the Di-
rector of National Intelligence, or the Director of the Cen-
tral Intelligence Agency contained in the National Security 
Act of 1947 (50 U.S.C. 401 et seq.), the Central Intel-
ligence Agency Act of 1949 (50 U.S.C. 403a et seq.), or 
any other law. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00063
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘§ 1009. Emerging threats task force, plan, campaign 
‘‘(a) EMERGING THREATS TASK FORCE.— 
‘‘(1) EMERGING AND CONTINUING THREATS CO-
ORDINATOR.—The Director shall designate or ap-
point a United States Emerging and Continuing 
Threats Coordinator to perform the duties of that 
position described in this section and such other du-
ties as may be determined by the Director. The Di-
rector shall determine whether the coordinator posi-
tion is a noncareer appointee in the Senior Executive 
Service or a career appointee at the GS–15 level (or 
equivalent) or above. 
‘‘(2) ESTABLISHMENT AND MONITORING.—The 
Emerging and Continuing Threats Coordinator (re-
ferred to in this section as the ‘Coordinator’) shall 
monitor evolving and emerging drug threats in the 
United States and shall serve as Chair of an Emerg-
ing Threats Task Force (in this section, referred to 
as the ‘task force’). The Director shall appoint other 
members of the task force, which shall include— 
‘‘(A) representatives from National Drug 
Control Program Agencies or other agencies; 
‘‘(B) representatives from State, local, and 
Tribal governments; 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00064
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(C) the Director of the National Drug 
Control Fusion Center established in section 
1013; and 
‘‘(D) representatives from other entities as 
determined to be necessary by the Director. 
‘‘(3) INFORMATION REVIEW AND SHARING.— 
‘‘(A) IN GENERAL.—The task force shall 
disseminate and facilitate the sharing with Fed-
eral, State, local, and Tribal officials and other 
entities as determined by the Director of perti-
nent information and data relating to the fol-
lowing: 
‘‘(i) Recent trends in drug supply and 
demand. 
‘‘(ii) Fatal and nonfatal overdoses. 
‘‘(iii) Demand for and availability of 
evidence-based 
substance 
use 
disorder 
treatment, including the extent of the 
unmet treatment need, and treatment ad-
mission trends. 
‘‘(iv) Recent trends in drug interdic-
tion, supply, and demand from State, local, 
and Tribal law enforcement agencies. 
‘‘(v) Other subject matter as deter-
mined necessary by the Director. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00065
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(B) CONTRACT, AGREEMENT, AND OTHER 
AUTHORITY.—The Director may award con-
tracts, enter into interagency agreements, man-
age individual projects, and conduct other ac-
tivities in support of the identification of emerg-
ing drug threats and in support of the develop-
ment, implementation, and assessment of any 
Emerging Threat Response Plan. 
‘‘(C) DATA ANALYSIS ACTIVITIES.—In sup-
port of the task force, the National Drug Con-
trol Fusion Center is authorized to conduct and 
provide to the task force the results of data 
analysis activities that the task force requests 
to aid in their review of recent trends in the 
data disseminated under subparagraph (A). 
‘‘(4) CRITERIA TO IDENTIFY EMERGING DRUG 
THREATS.—Not later than 60 days after the date on 
which a task force first meets, the task force shall 
develop and recommend to the Director criteria to be 
used to identify an emerging drug threat or the ter-
mination of an emerging drug threat designation 
based on information gathered by the task force in 
paragraph (2), statistical data, and other evidence. 
‘‘(5) MEETINGS.—The task force shall meet in 
person not less frequently than quarterly and at ad-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00066
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
ditional meetings if determined to be necessary by 
and at the call of the Chair to— 
‘‘(A) identify and discuss evolving and 
emerging drug trends in the United States 
using the criteria established in paragraph (3); 
‘‘(B) assist in the formulation of any plan 
described in subsection (c); 
‘‘(C) oversee implementation of the plan 
described in subsection (c); and 
‘‘(D) provide such other advice to the Co-
ordinator and Director concerning strategy and 
policies for emerging drug threats and trends as 
the task force determines to be appropriate. 
‘‘(b) DESIGNATION.— 
‘‘(1) IN GENERAL.—The Director, in consulta-
tion with the Coordinator, the task force, and the 
head of each National Drug Control Program Agen-
cy, may designate an emerging drug threat in the 
United States. 
‘‘(2) STANDARDS FOR DESIGNATION.—The Di-
rector, in consultation with the Coordinator, shall 
promulgate and make publicly available standards by 
which a designation under paragraph (1) and the 
termination of such designation may be made. In de-
veloping such standards, the Director shall consider 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00067
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
the recommendations of the task force and other cri-
teria the Director considers to be appropriate. 
‘‘(3) PUBLIC STATEMENT REQUIRED.—The Di-
rector shall publish a public written statement on 
the portal of the Office explaining the designation of 
an emerging drug threat or the termination of such 
designation and shall notify the appropriate congres-
sional committees of the availability of such state-
ment when a designation or termination of such des-
ignation has been made. 
‘‘(c) PLAN.— 
‘‘(1) PUBLIC
AVAILABILITY
OF
PLAN.—Not 
later than 60 days after making a designation under 
subsection (b), the Director shall publish and make 
publicly available an Emerging Threat Response 
Plan and notify the President and the appropriate 
congressional committees of such plan’s availability. 
‘‘(2) TIMING.—Not less frequently than every 
90 days after the date on which the plan is pub-
lished under paragraph (1), the Director shall up-
date the plan and report on implementation of the 
plan, until the Director issues the public statement 
required under subsection (b)(3) to terminate the 
emerging drug threat designation. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00068
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(3) CONTENTS OF AN EMERGING THREAT RE-
SPONSE PLAN.—The Director shall include in the 
plan— 
‘‘(A) a comprehensive strategic assessment 
of the emerging drug threat, including the cur-
rent availability of, demand for, and effective-
ness of evidence-based prevention, treatment, 
and enforcement programs and efforts to re-
spond to the emerging drug threat; 
‘‘(B) comprehensive, research-based, long- 
range, quantifiable goals for addressing the 
emerging drug threat, including for reducing 
the supply of the drug designated as the emerg-
ing drug threat and for expanding the avail-
ability and effectiveness of evidence-based sub-
stance use disorder treatment and prevention 
programs to reduce the demand for the emerg-
ing drug threat; 
‘‘(C) performance measures pertaining to 
the plan’s goals, including quantifiable and 
measurable objectives and specific targets; 
‘‘(D) the level of funding needed to imple-
ment the plan, including whether funding is 
available to be reprogrammed or transferred to 
support implementation of the plan or whether 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00069
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
additional appropriations are necessary to im-
plement the plan; 
‘‘(E) an implementation strategy for the 
education and public awareness campaign under 
subsection (d), including goals as described 
under subparagraph (B) and performance 
measures, objectives, and targets, as described 
under subparagraph (C); and 
‘‘(F) any other information necessary to 
inform the public of the status, progress, or re-
sponse of an emerging drug threat. 
‘‘(4) IMPLEMENTATION.— 
‘‘(A) IN
GENERAL.—Not later than 90 
days after the date on which a designation is 
made under subsection (b), the Director, in 
consultation with the President, the appropriate 
congressional committees, and the head of each 
National Drug Control Program Agency, shall 
issue guidance on implementation of the plan 
described in this subsection to the National 
Drug Control Program Agencies and any other 
relevant agency determined to be necessary by 
the Director. 
‘‘(B) 
COORDINATOR’S
RESPONSIBIL-
ITIES.—The Coordinator shall— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00070
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(i) direct the implementation of the 
plan among the agencies identified in the 
plan, State, local, and Tribal governments, 
and other relevant entities; 
‘‘(ii) facilitate information-sharing be-
tween agencies identified in the plan, 
State, local, and Tribal governments, and 
other relevant entities; and 
‘‘(iii) monitor implementation of the 
plan by coordinating the development and 
implementation of collection and reporting 
systems to support performance measure-
ment and adherence to the plan by agen-
cies identified in plan, where appropriate. 
‘‘(C) REPORTING.—Not later than 180 
days after the date on which a designation is 
made under subsection (b) and in accordance 
with paragraph (2)(C), the head of each agency 
identified in the plan shall submit to the Coor-
dinator a report on implementation of the plan. 
‘‘(d) EDUCATION
AND PUBLIC AWARENESS CAM-
PAIGN FOR EMERGING DRUG THREATS.— 
‘‘(1) IN
GENERAL.—Not later than 90 days 
after the date on which a designation is made under 
subsection (b), the Director shall, to the extent fea-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00071
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
sible and appropriate, establish and implement an 
evidence-based substance use prevention education 
and public awareness campaign to inform the public 
about the dangers of any drug designated as an 
emerging drug threat. Such campaign shall— 
‘‘(A) educate the public about the dangers 
of such drug, including patient and family edu-
cation about the characteristics and hazards of 
such drug and methods to safeguard against 
such dangers, including the safe disposal of 
such drug; 
‘‘(B) support evidence-based prevention 
programs targeting audiences’ attitudes, percep-
tions, and beliefs concerning substance use and 
intentions to initiate or continue such use; 
‘‘(C) increase awareness of the negative 
consequences of drug use; 
‘‘(D) encourage individuals affected by 
substance use disorders to seek treatment and 
provide such individuals with information on 
how to recognize addiction issues, what forms 
of evidence-based treatment options are avail-
able, and how to access such treatment; and 
‘‘(E) combat the stigma of addiction and 
substance use disorders, including the stigma of 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00072
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
Agencies as necessary to inform the National 
Drug Control Strategy. 
‘‘(C) Compile and analyze any data re-
quired to be collected under this chapter. 
‘‘(D) Disseminate technology, as appro-
priate, to States and local jurisdictions to en-
able or improve the collection of data on drug 
use, including the recordation of the occurrence 
of fatal and non-fatal drug overdoses. 
‘‘(E) Compile information collected by Na-
tional Drug Control Program Agencies on 
grants issued through any National Drug Con-
trol Program, including for any grant the fol-
lowing: 
‘‘(i) The recipient. 
‘‘(ii) The amount. 
‘‘(iii) The intended purpose. 
‘‘(iv) Any evidence of the efficacy of 
the outcomes achieved by the program 
funded through the grant. 
‘‘(v) Any assessments of how the 
grant met its intended purpose. 
‘‘(4) TOXICOLOGY SCREENING.— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00098
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS